RxDoctor Payments Data

Katie Shannon

Adult Health · Mason City, IANPI 1144829300

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Janssen Scientific Affairs, LLC accounts for 83.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $6,397 and has fallen 93.7% since, to $401 in 2025. Among adult health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,652in general payments, 2019–2025

Across 36 payments — averaging $212.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$6K
  • AbbVie$483
  • Johnson & Johnson$249
  • GSK$201
  • Boehringer Ingelheim$165
  • Amgen$145
  • plus $17 from 1 others

What the payments were for

  • Consulting fees$4,06353%
  • Travel & lodging$1,96626%
  • Food & beverage$1,37418%
  • Education$2493%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,652 in reported general payments places this provider in the 95th percentile of 77 adult health providers in Iowa.

See all adult health providers in Iowa

Medicare billing

Part B allowed, 2024
$67,368
Medicare patients
239
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab33$229,214
Enbrel SureclickEtanercept24$183,834
Orencia ClickjectAbatacept28$158,578
EnbrelEtanercept13$99,836
Enbrel MiniEtanercept13$91,285
Hydroxychloroquine Sulfate272$12,090
MethotrexateMethotrexate Sodium426$11,950
Leflunomide151$9,916
Sulfasalazine DrSulfasalazine51$3,181
Prednisone492$3,177
Sulfasalazine60$2,821
Pilocarpine Hcl13$1,389
Leucovorin Calcium46$683
Alendronate Sodium83$549
Folic Acid36$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$145$99,83613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 adult health providers in Iowa.

Other adult health in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →